177Lu-LNC1004 / Xiamen University, Dongcheng Pharma - LARVOL DELTA

Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) (clinicaltrials.gov) - P2 | N=35 | Recruiting | Sponsor: Institut Curie | Trial completion date: Jan 2030 ➔ Aug 2030 | Trial primary completion date: Jan 2029 ➔ Aug 2029

Trial completion date • Trial primary completion date • Oncology • Pancreatic Cancer • Solid Tumor

Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: The First Affiliated Hospital of Xiamen University | Recruiting ➔ Completed | N=20 ➔ 12

Enrollment change • Trial completion • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma

Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients with Various Solid Tumors (clinicaltrials.gov) - P2 | N=28 | Completed | Sponsor: The First Affiliated Hospital of Xiamen University | Recruiting ➔ Completed | Phase classification: P1 ➔ P2 | N=20 ➔ 28 | Trial completion date: Jun 2025 ➔ Oct 2024 | Trial primary completion date: Dec 2024 ➔ Sep 2024

Enrollment change • Phase classification • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: The First Affiliated Hospital of Xiamen University

New P1 trial • Oncology • Solid Tumor • FAP

Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: The First Affiliated Hospital of Xiamen University | Phase classification: P2 ➔ P1

Metastases • Phase classification • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma • FAP

Treatment Using 177Lu-DOTA-EB-FAPI in Patients With Radioactive Iodine Refractory Thyroid Cancer (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: The First Affiliated Hospital of Xiamen University | Not yet recruiting ➔ Recruiting

Enrollment open • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma • FAP

Treatment Using 177Lu-DOTA-EB-FAPI in Patients With Radioactive Iodine Refractory Thyroid Cancer (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xiamen University

New P2 trial • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma